In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Thomas Lund; Michael Tveden Gundesen; Annette Juul Vangsted; Carsten Helleberg; Einar Haukås; Trine Silkjær; Jon Thor Asmussen; Elena Manuela Teodorescu; Bo Amdi Jensen; Tobias Schmidt Slørdahl; Hareth Nahi; Anders Waage; Niels Abildgaard; Fredrik Schjesvold

doi:10.1038/s41408-024-01046-2

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Thomas Lund^*, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

13 Downloads (Pure)

Originalsprog	Engelsk
Artikelnummer	65
Tidsskrift	Blood Cancer Journal
Vol/bind	14
Antal sider	5
ISSN	2044-5385
DOI	https://doi.org/10.1038/s41408-024-01046-2
Status	Udgivet - 15. apr. 2024

Dokumenter og links

10.1038/s41408-024-01046-2Licens: CC BY

Open Access VersionForlagets udgivne version, 796 KBLicens: CC BY

1 Ph.d.-afhandling

Treatment and Monitoring of the Bone Disease in Multiple Myeloma Patients
Gundesen, M. T., 8. jul. 2024, Syddansk Universitet. Det Sundhedsvidenskabelige Fakultet. 138 s.
Publikation: Afhandling › Ph.d.-afhandling

Citationsformater

Lund, T., Gundesen, M. T., Juul Vangsted, A., Helleberg, C., Haukås, E., Silkjær, T., Asmussen, J. T., Manuela Teodorescu, E., Amdi Jensen, B., Schmidt Slørdahl, T., Nahi, H., Waage, A., Abildgaard, N., & Schjesvold, F. (2024). In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood Cancer Journal, 14, Artikel 65. https://doi.org/10.1038/s41408-024-01046-2

@article{3bcb3315826947e4b2b4d2dd88679635,

title = "In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease",

keywords = "Bone Density Conservation Agents/therapeutic use, Bone Diseases/drug therapy, Bone Neoplasms, Bone and Bones, Diphosphonates/therapeutic use, Humans, Multiple Myeloma/drug therapy, Zoledronic Acid/therapeutic use",

author = "Thomas Lund and Gundesen, {Michael Tveden} and {Juul Vangsted}, Annette and Carsten Helleberg and Einar Hauk{\aa}s and Trine Silkj{\ae}r and Asmussen, {Jon Thor} and {Manuela Teodorescu}, Elena and {Amdi Jensen}, Bo and {Schmidt Sl{\o}rdahl}, Tobias and Hareth Nahi and Anders Waage and Niels Abildgaard and Fredrik Schjesvold",

year = "2024",

month = apr,

day = "15",

doi = "10.1038/s41408-024-01046-2",

language = "English",

volume = "14",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

}

Lund, T, Gundesen, MT, Juul Vangsted, A, Helleberg, C, Haukås, E, Silkjær, T, Asmussen, JT, Manuela Teodorescu, E, Amdi Jensen, B, Schmidt Slørdahl, T, Nahi, H, Waage, A, Abildgaard, N & Schjesvold, F 2024, 'In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease', Blood Cancer Journal, bind 14, 65. https://doi.org/10.1038/s41408-024-01046-2

TY - JOUR

T1 - In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

AU - Lund, Thomas

AU - Gundesen, Michael Tveden

AU - Juul Vangsted, Annette

AU - Helleberg, Carsten

AU - Haukås, Einar

AU - Silkjær, Trine

AU - Asmussen, Jon Thor

AU - Manuela Teodorescu, Elena

AU - Amdi Jensen, Bo

AU - Schmidt Slørdahl, Tobias

AU - Nahi, Hareth

AU - Waage, Anders

AU - Abildgaard, Niels

AU - Schjesvold, Fredrik

PY - 2024/4/15

Y1 - 2024/4/15

KW - Bone Density Conservation Agents/therapeutic use

KW - Bone Diseases/drug therapy

KW - Bone Neoplasms

KW - Bone and Bones

KW - Diphosphonates/therapeutic use

KW - Humans

KW - Multiple Myeloma/drug therapy

KW - Zoledronic Acid/therapeutic use

U2 - 10.1038/s41408-024-01046-2

DO - 10.1038/s41408-024-01046-2

M3 - Comment/debate

C2 - 38622134

AN - SCOPUS:85190364394

SN - 2044-5385

VL - 14

JO - Blood Cancer Journal

JF - Blood Cancer Journal

M1 - 65

ER -

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Dokumenter og links

Relaterede publikationer

Treatment and Monitoring of the Bone Disease in Multiple Myeloma Patients

Citationsformater